Acquisition of Kaiku Health by the swedish company Elekta

We are thrilled to  announce the successful exit deal for Kaiku Health, a Debiopharm’s investment portfolio company, and its acquisition by Elekta. This acquisition allows thousands of cancer treatment centers to gain access to the start-up’s novel digital patient monitoring platform. As stated Tanja Dowe, our CEO:

It’s really thrilling to see our start-up investment companies grow and move to the next step of reaching more of the patients who can benefit from their innovation.  The growing patient base through Elekta will strengthen Kaiku Health’s capabilities to develop patient-centric and outcome-driven solutions for cancer patients, in some cases in collaboration with pharmaceutical companies. In the era of precision medicine, these outcomes play an important role for the development of pharmaceutical therapies.

You can access the full press release here.